Name of Blue Advantage Policy:
Corneal Collagen Cross-Linking

Policy #:639       Latest Review Date: March 2021
Category: Medical       Policy Grade: A

BACKGROUND:

Blue Advantage medical policy does not conflict with Local Coverage Determinations (LCDs), Local Medical Review Policies (LMRPs) or National Coverage Determinations (NCDs) or with coverage provisions in Medicare manuals, instructions or operational policy letters. In order to be covered by Blue Advantage the service shall be reasonable and necessary under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). The service is considered reasonable and necessary if it is determined that the service is:

1. Safe and effective;
2. Not experimental or investigational*;
3. Appropriate, including duration and frequency that is considered appropriate for the service, in terms of whether it is:
   • Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient’s condition or to improve the function of a malformed body member;
   • Furnished in a setting appropriate to the patient’s medical needs and condition;
   • Ordered and furnished by qualified personnel;
   • One that meets, but does not exceed, the patient’s medical need; and
   • At least as beneficial as an existing and available medically appropriate alternative.

*Routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000 which meet the requirements of the Clinical Trials NCD are considered reasonable and necessary by Medicare. Providers should bill Original Medicare for covered services that are related to clinical trials that meet Medicare requirements (Refer to Medicare National Coverage Determinations Manual, Chapter 1, Section 310 and Medicare Claims Processing Manual Chapter 32, Sections 69.0-69.11).
POLICY:
Blue Advantage will treat corneal collagen cross-linking using riboflavin and ultraviolet A, as a covered benefit for treatment of progressive keratoconus in patients who have failed conservative treatment (e.g. spectacle correction, rigid contact lens).

Progressive keratoconus is defined as 1 or more of the following:
• An increase of 1 diopter (D) in the steepest keratometry value
• An increase of 1 diopter (D) in regular astigmatism evaluated by subjective manifest refraction
• A myopic shift (decrease in the spherical equivalent) of 0.50 D on subjective manifest refraction
• A decrease ≥0.1 mm in the back optical zone radius in rigid contact lens wearers where other information was not available.

Blue Advantage will treat corneal collagen cross-linking using riboflavin and ultraviolet A as a noncovered benefit and as investigational for all other indications.

Blue Advantage will not cover complications or later procedures/surgery, even if medically necessary, related to the treatment of corneal ectasia following refractive surgery (e.g. LASIK) which is a benefit exclusion.

Blue Advantage does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Advantage administers benefits based on the members' contract and medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

DESCRIPTION OF PROCEDURE OR SERVICE:
Corneal collagen cross-linking (CXL) is a photochemical procedure approved by the Food and Drug Administration for the treatment of progressive keratoconus and corneal ectasia. Keratoconus is a dystrophy of the cornea characterized by progressive deformation (steepening) of the cornea while corneal ectasia is keratoconus that occurs after refractive surgery. Both lead to functional loss of vision and need for corneal transplantation.

Treatment of Keratoconus and Ectasia
The initial treatment for keratoconus often consists of hard contact lenses. A variety of keratorefractive procedures have also been attempted, broadly divided into subtractive and additive techniques. Subtractive techniques include photorefractive keratectomy or laser in situ keratomileusis (LASIK), although generally, results of these techniques have been poor. Implantation of intrastromal corneal ring segments is an additive technique in which the implants are intended to reinforce the cornea, prevent further deterioration, and potentially obviate the need for penetrating keratoplasty. Penetrating keratoplasty (i.e., corneal grafting) is the last line
of treatment. About 20% of patients with keratoconus will require corneal transplantation. All of these treatments attempt to improve the refractive errors, but are not disease-modifying.

Treatment options for ectasia include intraocular pressure-lowering drugs, and intracorneal ring segments. Frequently, a penetrating keratoplasty is required.

None of the currently available treatment options for keratoconus and corneal ectasia halt the progression of disease, and corneal transplantation is the only option available when functional vision can no longer be achieved.

Corneal collagen cross-linking (CXL) has the potential to slow the progression of disease. It is performed with the photosensitizer riboflavin (vitamin B₂) and ultraviolet A (UVA) irradiation. There are two protocols for CXL.

1. Epithelium-off CXL (also known as “epi-off”): In this method, about eight mm of the central corneal epithelium is removed under topical anesthesia to allow better diffusion of the photosensitizer riboflavin into the stroma. Following de-epithelialization, a solution with riboflavin is applied to the cornea (every one to three minutes for 30 minutes) until the stroma is completely penetrated. The cornea is then irradiated for 30 minutes with ultraviolet A 370 nm, a maximal wavelength for absorption by riboflavin, while the riboflavin continues to be applied. The interaction of riboflavin and UVA causes the formation of reactive oxygen species, leading to additional covalent bonds (cross-linking) between collagen molecules, resulting in stiffening of the cornea. Theoretically, by using a homogeneous light source and absorption by riboflavin, the structures beyond a 400-micron thick stroma (endothelium, anterior chamber, iris, lens, retina) are not exposed to an ultraviolet dose that is above the cytotoxic threshold.

2. Epithelium-on CXL (also known as “epi-on” or transepithelial): In this method, the corneal epithelial surface is left intact (or may be partially disrupted) and a longer riboflavin loading time is needed.

Currently, the only CXL treatment approved by the Food and Drug Administration (FDA) is the epithelium-off method. There are no FDA-approved CXL treatments using the epithelium-on method. CXL is being evaluated primarily for corneal stabilization in patients with progressive corneal thinning, such as keratoconus and corneal ectasia following refractive surgery. CXL may also have anti-edematous and antimicrobial properties.

**KEY POINTS:**
The most recent literature update was performed through February 9, 2021.

**Summary of Evidence**
For individuals who have progressive keratoconus who receive CXL using riboflavin and ultraviolet A, the evidence includes multiple RCTs, systematic reviews, and nonrandomized studies. Relevant outcomes are change in disease status, functional outcomes, and treatment-related morbidity. In both pivotal RCTs, the primary end point (an intermediate outcome) of reducing maximum corneal curvature (Kmax) by one D was achieved at month three and maintained at months six and 12 in CXL-treated patients compared with sham controls. In both RCTs, the difference in mean change in Kmax from baseline to 12 months was 1.9 D and 2.3 D,
respectively, favoring the CXL-treated patients. Several other studies measured visual acuity and found significant and lasting improvements in corrected visual acuity and other measures with CXL. Long-term follow-up for visual acuity outcomes are needed. The adverse events associated with CXL include corneal opacity (haze), corneal epithelial defects, and other ocular findings. Most adverse events resolved in the first month but continued in a few (1%-6%) patients for six to 12 months. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Practice Guidelines and Position Statements
National Institute for Health and Care Excellence
In 2013, the National Institute for Health and Care Excellence (NICE) issued guidance on corneal collagen cross-linking using riboflavin and ultraviolet A, updating its guidance based on a 2009 systematic review of primarily low-quality evidence; review authors declared no financial conflicts of interest. The 2013 guidance stratified recommendations for corneal collagen cross-linking as follows:

“Most of the published evidence on photochemical corneal collagen cross-linkage using riboflavin and ultraviolet A (UVA) for keratoconus and keratectasia relates to the technique known as ‘epithelium-off corneal collagen cross-linking’. ‘Epithelium-on (transepithelial) corneal collagen cross-linking’ is a more recent technique and less evidence is available on its safety and efficacy. Either procedure (epithelium-off or epithelium-on corneal collagen cross-linking) can be combined with other interventions, and the evidence base for these combination procedures (known as ‘corneal collagen cross-linking plus’) is also limited. Therefore, different recommendations apply to the variants of this procedure, as follows.

1.1 Current evidence on the safety and efficacy of epithelium-off corneal collagen cross-linking for keratoconus and keratectasia is adequate in quality and quantity. Therefore, this procedure can be used provided that normal arrangements are in place for clinical governance, consent and audit.

1.2 Current evidence on the safety and efficacy of epithelium-on (transepithelial) corneal collagen cross-linking, and the combination (corneal collagen cross-linking plus) procedures for keratoconus and keratectasia is inadequate in quantity and quality. Therefore, these procedures should only be used with special arrangements for clinical governance, consent and audit or research.”

U.S. Preventive Services Task Force Recommendations
Not applicable.

KEY WORDS:
Corneal Collagen Cross-linking, refractory surgery, LASIK, Keratoconus, Photrexa Viscous®; Avedro, Photrexa®; Avedro, corneal ectasia, CXL, KXL

APPROVED BY GOVERNING BODIES:
In 2016, riboflavin 5'-phosphate in 20% dextran ophthalmic solution (Photrexa Viscous®; Avedro) and riboflavin 5'-phosphate ophthalmic solution (Photrexa®; Avedro) were approved
by the U.S. Food and Drug Administration for use with KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia after refractive surgery.

**BENEFIT APPLICATION:**
Coverage is subject to member’s specific benefits. Group specific policy will supersede this policy when applicable.

**CURRENT CODING:**
**CPT Codes:**

| 0402T | Collagen cross-linking of cornea (including removal of the corneal epithelium and intraoperative pachymetry when performed) |

**HCPCS Codes:**

| J2787 | Riboflavin 5'-phosphate, ophthalmic solution, up to 3 mL |

**REFERENCES:**


2. Avedro Inc. Avedro Briefing Package for Joint Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Device Panel of the Medical Devices Advisory Committee NDA 203324: Photorexa Viscous and Photorexa (riboflavin ophthalmic solution) and KXL System (UVA light source) Avedro, Inc. 2015; Accessed February 7, 2017


POLICY HISTORY:
Adopted for Blue Advantage, April 2017
Available for comment April 28 through June 11, 2017
Medical Policy Group, March 2018
Medical Policy Group, June 2018
Medical Policy Group, December 2018: 2019 Annual Coding Update
Medical Policy Group, April 2019
Medical Policy Group, March 2020
Medical Policy Group, March 2021

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member’s plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield’s administration of plan contracts.